China's Pharma Industry Bets Big on AI After Decade of Innovation

China's pharmaceutical industry has completed a sweeping 10-year transformation, leveraging artificial intelligence, gene editing, and advanced manufacturing to challenge Western dominance in drug discovery and medical devices. A comprehensive review published by the Chinese Academy of Engineering Sciences details how the country's $230 billion pharma sector is now positioning AI at the center of its next growth phase.

The report, released through the academy's official journal, outlines how emerging technologies — from large language models to cloud computing — are fundamentally reshaping China's approach to healthcare innovation. For Western pharmaceutical giants and AI companies alike, the implications are significant.

Key Takeaways at a Glance

• China's pharmaceutical industry now spans chemical drugs, biologics, traditional Chinese medicine, medical devices, and pharmaceutical packaging materials
• AI-driven drug discovery has become a central pillar of China's 'Healthy China 2030' national strategy
• Gene editing and cell and gene therapy (CGT) technologies are opening new treatment pathways for rare and complex diseases
• Domestic production of high-performance medical devices is actively replacing foreign technology monopolies
• Cross-sector convergence of AI, life sciences, big data, and advanced manufacturing is accelerating industry transformation
• The country aims to build fully self-controlled innovation chains, industrial chains, and supply chains in pharmaceuticals

AI Reshapes China's Drug Discovery Pipeline

The integration of artificial intelligence into pharmaceutical R&D represents perhaps the most consequential shift documented in the decade-long review. Chinese biotech firms and research institutions have rapidly adopted AI-powered platforms for target identification, molecular screening, and clinical trial optimization.

This mirrors — and in some areas rivals — similar efforts by Western companies like Insilico Medicine (which itself has deep roots in both US and Chinese research ecosystems), Recursion Pharmaceuticals, and Isomorphic Labs (a Google DeepMind spinoff). However, China's approach differs in its scale of government coordination and its emphasis on integrating AI across the entire pharmaceutical value chain, not just early-stage discovery.

Large language models (LLMs) and foundation models trained on biomedical data are increasingly being deployed in Chinese pharmaceutical labs. Companies like Baidu and Tencent have released healthcare-specific AI models, while startups such as XtalPi have raised hundreds of millions of dollars to apply AI and cloud computing to drug design. XtalPi alone has secured over $700 million in funding since its founding, making it one of the world's best-funded AI-pharma startups.

Medical Devices: Breaking Foreign Technology Monopolies

One of the report's most striking findings concerns high-performance medical devices. For decades, China relied heavily on imports from companies like Siemens Healthineers, GE HealthCare, and Philips for advanced imaging equipment, surgical robots, and diagnostic systems.

That dependency is rapidly shrinking. Chinese companies including Mindray, United Imaging Healthcare, and Micro-Port Scientific have developed domestically manufactured alternatives that now compete on both quality and price. United Imaging, for instance, has shipped its PET/CT and MRI systems to hospitals across Europe, Latin America, and Southeast Asia — directly challenging the traditional 'Big 3' of medical imaging.

The AI angle here is critical. Many of these new Chinese medical devices incorporate AI-powered diagnostic algorithms, automated image analysis, and cloud-connected monitoring systems. This convergence of hardware innovation and AI software gives Chinese manufacturers a potential edge in emerging markets where cost-effectiveness is paramount.

• Mindray reported over $4.5 billion in revenue in 2023, with AI-enhanced monitoring and diagnostic systems driving growth
• United Imaging completed its IPO on the Shanghai Stock Exchange, raising approximately $860 million
• Micro-Port has expanded its surgical robotics division, competing with Intuitive Surgical's da Vinci platform
• Chinese medical AI startups received over $2 billion in combined funding between 2019 and 2024

Gene Editing and Cell Therapy Enter the Mainstream

The review highlights gene editing and cell and gene therapy (CGT) as frontier technologies that are opening entirely new treatment paradigms. China has been particularly aggressive in advancing CRISPR-based therapies and CAR-T cell treatments.

In fact, China approved its first CAR-T therapy products in 2021 — manufactured by domestic companies like JW Therapeutics (in partnership with Juno/Bristol Myers Squibb) and Legend Biotech (whose Carvykti product, developed with Johnson & Johnson, received FDA approval in 2022). These developments illustrate how China's pharmaceutical innovation is no longer isolated from global markets but increasingly intertwined with them.

Compared to the United States, where Vertex Pharmaceuticals and CRISPR Therapeutics launched the groundbreaking Casgevy sickle cell treatment in late 2023, China's gene therapy pipeline is broader but generally earlier-stage. The academy's report suggests that AI-assisted gene editing design tools and computational biology platforms will be essential to accelerating these programs through clinical development.

The 'Healthy China 2030' Strategy Drives Policy Alignment

Underpinning all of these technological advances is the 'Healthy China 2030' national strategy, a sweeping policy framework that treats pharmaceutical innovation as a matter of national security and economic competitiveness.

The strategy explicitly calls for:

• Building autonomous and controllable pharmaceutical supply chains to reduce dependence on foreign APIs and technologies
• Accelerating the adoption of AI, big data, and cloud computing across drug development, manufacturing, and distribution
• Strengthening intellectual property protections to incentivize domestic innovation
• Expanding international regulatory cooperation to facilitate global market access for Chinese-developed drugs and devices
• Investing in advanced manufacturing capabilities, including continuous manufacturing and smart factory technologies

For Western pharmaceutical companies, this policy environment creates both competitive pressures and partnership opportunities. Several major US and European firms — including AstraZeneca, Novartis, and Roche — maintain significant R&D operations in China and have actively collaborated with Chinese AI-pharma startups.

What This Means for the Global AI-Pharma Landscape

The implications of China's pharmaceutical AI push extend well beyond its borders. As Chinese companies develop increasingly sophisticated AI tools for drug discovery and medical devices, the global competitive landscape is shifting in several important ways.

First, the cost of AI-driven drug discovery is declining globally as Chinese companies introduce lower-cost alternatives to platforms offered by Western firms like Schrödinger and Atomwise. This could democratize access to AI-powered pharma tools, particularly for smaller biotech companies and academic researchers.

Second, the medical device market is becoming more competitive. Chinese AI-enabled devices are gaining regulatory approvals in Europe (CE marking) and other markets, putting pricing pressure on established players.

Third, the talent pipeline is evolving. China now produces more STEM graduates annually than the US and EU combined, and a growing proportion of them specialize in the intersection of AI and life sciences. This talent base fuels both domestic innovation and — through emigration and international collaboration — global research ecosystems.

Looking Ahead: The Next Decade of AI-Pharma Convergence

The Chinese Academy of Engineering Sciences' review is ultimately forward-looking, identifying several trends that will define the next 10 years of pharmaceutical innovation.

Foundation models for biology — similar to what Meta has done with ESMFold or what Google DeepMind achieved with AlphaFold — are expected to become standard tools in Chinese pharmaceutical R&D by 2030. The Chinese government has signaled its intention to fund development of domain-specific large models for healthcare applications.

Smart manufacturing will transform production. The report envisions AI-optimized continuous manufacturing lines that can adapt in real-time to quality control data, reducing waste and accelerating time-to-market for new drugs.

International competition and cooperation will intensify. As both the US and China pour billions into AI-driven healthcare innovation, regulatory frameworks, data-sharing agreements, and IP protections will become critical points of negotiation.

For Western companies and investors watching this space, the message is clear: China's pharmaceutical industry is no longer a low-cost manufacturing hub. It is rapidly becoming an innovation leader — and AI is the engine driving that transformation. The next decade will determine whether this shift leads to greater global collaboration or deeper technological rivalry.